AstraZeneca's ENHERTU Priority Review Signals Shift in Early Breast Cancer Treatment
Event summary
- AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU has received Priority Review from the FDA.
- The FDA's action date for regulatory decision is anticipated during Q3 2026.
- The sBLA concerns ENHERTU's use as a post-neoadjuvant treatment for adult patients with HER2-positive early breast cancer.
- DESTINY-Breast05 trial data showed a 53% reduction in invasive disease-free survival (IDFS) with ENHERTU compared to T-DM1.
The big picture
The Priority Review designation underscores the unmet need for improved treatments in HER2-positive early breast cancer, a market segment representing roughly 20% of all breast cancer cases. ENHERTU's superior IDFS results in the DESTINY-Breast05 trial position it to potentially displace T-DM1, a therapy with approximately $1 billion in annual revenue. This approval, if granted, could significantly impact AstraZeneca's oncology portfolio and further solidify its presence in the rapidly evolving ADC market.
What we're watching
- Regulatory Approval
- The FDA's decision in Q3 2026 will be critical, as approval would significantly expand ENHERTU's market and solidify its position in the early breast cancer treatment landscape.
- Market Adoption
- The pace at which oncologists adopt ENHERTU as a post-neoadjuvant treatment will depend on reimbursement rates and comparative effectiveness data against existing therapies.
- Competitive Response
- How T-DM1 and other competitors react to ENHERTU's potential approval, particularly through clinical trial design and pricing strategies, will shape the competitive dynamics in this segment.
Related topics